Principal Investigator (PI)
The Foundation is providing £85,570 in support.
Julio Alonso Padilla
GSK provides in-kind contributions (including facilities and expertise from supporting scientists for HTS and GSK collection of compounds).
To run a specific test known as a Trypanosome cell-based assay to help identify new drugs for the treatment of Chagas disease. A significant part of the research involves conducting high-throughput screening (HTS) to find specific inhibitors of the infection.
The objective of the HTS is to find several chemical compounds which demonstrate specific activity relevant to Chagas disease that could subsequently be developed into a lead for the treatment of this disease.
"This type of screening is only possible with access to facilities at a large pharmaceutical company such as GSK. The amount of resources, equipment and expertise needed to screen a compound collection of the size that will be analysed in this campaign, would be unfeasible elsewhere". Julio Alonso Padilla (Open Lab Scientist)